{"id":"genotype-guided-ppi-dosing","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL6068521","moleculeType":"Small molecule","molecularWeight":"815.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a pharmacogenomic dosing strategy rather than a novel drug. It uses genetic testing of CYP2C19 variants to classify patients as poor, intermediate, extensive, or ultra-rapid metabolizers, then adjusts PPI doses accordingly. Poor metabolizers require lower doses to avoid toxicity, while ultra-rapid metabolizers may need higher doses for therapeutic effect.","oneSentence":"Genotype-guided PPI dosing optimizes proton pump inhibitor therapy by tailoring doses based on individual CYP2C19 metabolizer status to improve efficacy and safety.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:53.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD) — genotype-guided dosing"},{"name":"Peptic ulcer disease — genotype-guided dosing"},{"name":"Acid-related disorders requiring PPI therapy — genotype-guided dosing"}]},"trialDetails":[{"nctId":"NCT02930824","phase":"NA","title":"Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-12","conditions":"Gastroesophageal Reflux Disease","enrollment":185},{"nctId":"NCT02794844","phase":"PHASE4","title":"Implementation of PPI Medication PGX Testing","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2016-07-21","conditions":"Gastroesophageal Reflux","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prilosec","Nexium","Prevacid","Proton Pump Inhibitor"],"phase":"marketed","status":"active","brandName":"Genotype Guided PPI Dosing","genericName":"Genotype Guided PPI Dosing","companyName":"Nemours Children's Clinic","companyId":"nemours-children-s-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Genotype-guided PPI dosing optimizes proton pump inhibitor therapy by tailoring doses based on individual CYP2C19 metabolizer status to improve efficacy and safety. Used for Gastroesophageal reflux disease (GERD) — genotype-guided dosing, Peptic ulcer disease — genotype-guided dosing, Acid-related disorders requiring PPI therapy — genotype-guided dosing.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}